These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Issues and progress with protein kinase inhibitors for cancer treatment. Dancey J; Sausville EA Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029 [TBL] [Abstract][Full Text] [Related]
23. Targeting growth factors and angiogenesis; using small molecules in malignancy. Wanebo HJ; Argiris A; Bergsland E; Agarwala S; Rugo H Cancer Metastasis Rev; 2006 Jun; 25(2):279-92. PubMed ID: 16770540 [TBL] [Abstract][Full Text] [Related]
24. Cyclin-dependent kinases as targets for cancer therapy. Senderowicz AM Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205 [TBL] [Abstract][Full Text] [Related]
25. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Sawyers CL Genes Dev; 2003 Dec; 17(24):2998-3010. PubMed ID: 14701871 [No Abstract] [Full Text] [Related]
26. X chemotherapy, myth and realities. Thomas M; Pavithran K J Indian Med Assoc; 2005 Sep; 103(9):489-90, 492, 494. PubMed ID: 16493871 [TBL] [Abstract][Full Text] [Related]
27. Cancer chemotherapeutic agents. Krakoff IH CA Cancer J Clin; 1973; 23(4):209-19. PubMed ID: 4200099 [No Abstract] [Full Text] [Related]
28. New targets for cancer chemotherapy. Murgo AJ; Dancey J; Eckhardt SG; Hidalgo M; Arbuck SG; Zerivitz K; Blaylock BA Cancer Chemother Biol Response Modif; 2002; 20():239-72. PubMed ID: 12703208 [No Abstract] [Full Text] [Related]
30. Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. Clark JW Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-19-S18-24. PubMed ID: 9420017 [TBL] [Abstract][Full Text] [Related]
31. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Fry DW Anticancer Drug Des; 2000 Feb; 15(1):3-16. PubMed ID: 10888032 [TBL] [Abstract][Full Text] [Related]
32. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Epping MT; Bernards R Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293 [TBL] [Abstract][Full Text] [Related]
33. HDAC inhibitors: a potential new category of anti-tumor agents. Pan LN; Lu J; Huang B Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313 [TBL] [Abstract][Full Text] [Related]
34. New hope for cancer. Lemonick MD; Park A Time; 2001 May; 157(21):62-9. PubMed ID: 11393038 [No Abstract] [Full Text] [Related]
36. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy. Senderowicz AM Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013 [TBL] [Abstract][Full Text] [Related]
37. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance]. Pourquier P; Pommier Y Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078 [TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors in cancer therapy. Fouladi M Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962 [No Abstract] [Full Text] [Related]
39. Cancer chemotherapy. Med Lett Drugs Ther; 1983 Jan; 25(626):1-8. PubMed ID: 6848903 [No Abstract] [Full Text] [Related]
40. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. Awada A; Mano M; Hendlisz A; Piccart M Expert Rev Anticancer Ther; 2004 Feb; 4(1):53-60. PubMed ID: 14748657 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]